AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com

Harvard Bioscience, Inc. Q3 2026 Earnings Call Summary

Harvard Bioscience reported Q3 2026 revenue growth of 8%, driven by CRO demand and new product innovations. China revenue rose 31% year-over-year. Gross margins were pressured by lower-margin products. Full-year revenue guidance was reaffirmed at 3-5% growth, but adjusted EBITDA guidance was lowered. Project Viking is expected to deliver cost savings in 2027. Management expects to launch a bioproduction version of electroporation technology in mid-2027.

Original reporting
finance.yahoo.com
Published Nov 10, 2026, 5:57 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 6:13 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Harvard Bioscience, Inc. Q3 2026 Earnings Call Summary — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

Med
01

Why it matters

Guidance downgrade and margin pressure could trigger a sell‑off, while long‑term cost savings from Project Viking may support a rebound.

02

Market read

Earnings guidance and structural changes are the primary drivers for short‑term price movement.

03

What to watch

Strong CRO demand and China expansion may provide upside if execution accelerates.

Relevance 7/10Novelty 7/10Timing: post‑earnings Q3 2026 release

Background

Harvard Bioscience reported Q3 2026 results, highlighting 8% revenue growth, China expansion, and a reverse stock split.

Market effects

Sector

Biotech research tools sector may see modest re‑rating as peers assess similar margin pressures.

Regional

China revenue growth offsets some U.S. margin concerns, but overall sentiment remains cautious.

Global

Limited to investors tracking niche life‑science equipment stocks.

Counterpoint

What could challenge this read

Cost‑saving initiatives from Project Viking could improve margins faster than guidance suggests.

Key entities

  • company
    Harvard Bioscience, Inc.

    US‑listed life‑science equipment provider (ticker HBS).

Read at source← All news

StoryHarvard Bioscience reports Q3 2026 revenue up 8% but margin compression

Also covered by

2 outlets

Related articles

$HBIOHigh

Harvard Bioscience (HBIO) Q3 2026 Earnings Call Transcript

Harvard Bioscience (HBIO) reported Q3 2026 revenue of $22.2M, up 8% YoY, driven by CRO and distribution partner demand. Adjusted EBITDA was $1.8M, impacted by lower-margin products. The company reaffirmed full-year revenue guidance of 3-5% growth and adjusted gross margin target of 57-59%. Project Viking, a manufacturing consolidation plan, is on track for 2027 completion, expected to generate $3M in cost savings.

finance.yahoo.com
$HBIOMed

Harvard Bioscience Announces Third Quarter 2026 Financial Results

HARVARD BIOSCIENCE INC (HBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Harvard Bioscience Announces Third Quarter 2026 Financial Results · Third Quarter 2026 Revenue Growth of 8% Year Over Year to $22.2 Million · Reaffirms Full Year 2026 Revenue Guidance of 3%-5% Year Over Year Growth HOLLISTON, Mass., November 10, 2026 (GLOBE NEWSWIRE)

SEC EDGAR 8-K
$HBIOMedAI 8/10

Harvard Bioscience (HBIO) Q2 2026 Earnings Call Transcript

Harvard Bioscience (HBIO) reported Q2 2026 revenue of $22.7M, up 11%, and adjusted EBITDA of $1.7M, up 11%. Full-year revenue guidance was raised to 3-5% growth, but gross margin guidance was lowered to 57-59% due to product and geographic mix shifts. The company expects $3M in cost savings from Project Viking in 2027. Americas and APAC regions showed strong growth, while Europe grew modestly. Adjusted EPS was -$0.14, and Q3 revenue guidance is $21.0M-$22.6M.

fool.com
$HBIOMed

Harvard Bioscience, Inc. Q2 2026 Earnings Call Summary

Harvard Bioscience (HBIO) reported Q2 2026 revenue up 11%, driven by CRO demand and double-digit growth in telemetry and CMT portfolios. China sales rose on its “Made in China” BTX line. Recurring revenue reached 55%. Full-year guidance raised to 3% to 5% growth, but adjusted gross margin cut 100 bps to 57% to 59%, with Project Viking cost savings.

yahoo.com